NZ511034A - Methods of downmodulating the immune response to therapeutic proteins - Google Patents

Methods of downmodulating the immune response to therapeutic proteins

Info

Publication number
NZ511034A
NZ511034A NZ511034A NZ51103499A NZ511034A NZ 511034 A NZ511034 A NZ 511034A NZ 511034 A NZ511034 A NZ 511034A NZ 51103499 A NZ51103499 A NZ 51103499A NZ 511034 A NZ511034 A NZ 511034A
Authority
NZ
New Zealand
Prior art keywords
immune response
downmodulating
methods
therapeutic proteins
composition
Prior art date
Application number
NZ511034A
Other languages
English (en)
Inventor
Jiahua Qian
Leon W Hoyer
Mary Collins
Gary Gray
Original Assignee
American Nat Red Cross
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Nat Red Cross, Inst Genetics Llc filed Critical American Nat Red Cross
Publication of NZ511034A publication Critical patent/NZ511034A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ511034A 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins NZ511034A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques

Publications (1)

Publication Number Publication Date
NZ511034A true NZ511034A (en) 2004-03-26

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ511034A NZ511034A (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Country Status (21)

Country Link
EP (1) EP1115423A1 (fr)
JP (1) JP2002526455A (fr)
KR (1) KR20010085830A (fr)
CN (1) CN1331602A (fr)
AU (1) AU761206B2 (fr)
BR (1) BR9913991A (fr)
CA (1) CA2343916A1 (fr)
CZ (1) CZ20011021A3 (fr)
EA (1) EA005236B1 (fr)
HK (1) HK1039059A1 (fr)
HU (1) HUP0103960A3 (fr)
IL (1) IL142069A0 (fr)
LT (1) LT4920B (fr)
LV (1) LV12768B (fr)
MX (1) MXPA01002898A (fr)
NO (1) NO20011412L (fr)
NZ (1) NZ511034A (fr)
PL (1) PL346796A1 (fr)
SI (1) SI20626A (fr)
WO (1) WO2000016801A1 (fr)
ZA (1) ZA200103156B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US20020031508A1 (en) * 2000-05-19 2002-03-14 Wagner Denisa D. Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
EP1636579A4 (fr) * 2003-06-10 2011-10-05 Smiths Detection Inc Ensemble detecteur
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2580812A1 (fr) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Recepteur ctla, proteines hybrides qui le contiennent et ses applications
WO1993009804A1 (fr) 1991-11-18 1993-05-27 The Scripps Research Institute Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP0776217A1 (fr) * 1994-08-19 1997-06-04 Novo Nordisk A/S Methode de traitement d'un patient a l'aide d'un compose biologiquement actif
EP0804076A4 (fr) * 1994-10-19 1998-10-21 Genetic Therapy Inc Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法
JP2002504910A (ja) * 1997-06-20 2002-02-12 バイオジェン，インコーポレイテッド 治療用タンパク質阻害因子症候群のためのｃｄ１５４遮断治療
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
CN1331602A (zh) 2002-01-16
SI20626A (sl) 2002-02-28
NO20011412L (no) 2001-05-16
EA200100385A1 (ru) 2001-10-22
MXPA01002898A (es) 2002-06-04
EP1115423A1 (fr) 2001-07-18
HUP0103960A2 (hu) 2002-02-28
WO2000016801A1 (fr) 2000-03-30
NO20011412D0 (no) 2001-03-20
HK1039059A1 (zh) 2002-04-12
AU6057899A (en) 2000-04-10
LT2001045A (en) 2002-01-25
BR9913991A (pt) 2001-07-03
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
EA005236B1 (ru) 2004-12-30
HUP0103960A3 (en) 2003-09-29
PL346796A1 (en) 2002-02-25
ZA200103156B (en) 2002-07-18
CA2343916A1 (fr) 2000-03-30
LT4920B (lt) 2002-06-25
LV12768A (en) 2001-12-20
LV12768B (lv) 2002-06-20
IL142069A0 (en) 2002-03-10
KR20010085830A (ko) 2001-09-07
AU761206B2 (en) 2003-05-29
WO2000016801A9 (fr) 2000-10-26

Similar Documents

Publication Publication Date Title
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
EA200000445A1 (ru) Способы лечения состояния гиперкоагуляции или приобретенной недостаточности белка c
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
FI961621A0 (fi) Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
TR200000015T2 (tr) Bileşikler ve metodlar
IL160641A0 (en) Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
CA2413190A1 (fr) Methodes de traitement de maladies rhumatismales a l'aide d'une molecule ctla4 soluble
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
DK0915974T3 (da) Modificerede tie-2 receptor-ligander
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
DE69434384D1 (de) Metalkomplexbildner
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
WO1997029199A3 (fr) Peptides pour l'antigene prostatique specifique et leurs utilisations
EP1064005A4 (fr) Utilisation du recepteur des activateurs du plasminogene d'urokinase comme cible pour le depistage des metastases
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AMERICAN RED CROSS, US

Free format text: OLD OWNER(S): AMERICAN RED CROSS; GENETICS INSTITUTE, INC.

Owner name: GENETICS INSTITUTE, US

Free format text: OLD OWNER(S): AMERICAN RED CROSS; GENETICS INSTITUTE, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)